

# PATENT SPECIFICATION

(11) 1 299 557

NO DRAWINGS



1 299 557

- (21) Application No. 25749/71 (22) Filed 19 April 1971  
 (31) Convention Application No. 6838 (32) Filed 2 April 1970 in  
 (33) Yugoslavia (YU)  
 (45) Complete Specification published 13 Dec. 1972  
 (51) International Classification C07D 43/22  
 (52) Index at acceptance  
 C2C 179—27X—279 182—198—281 213 214 220 226 22Y  
 250 252 255 25Y 28X 342 34Y 351 352 360 363  
 36Y 604 62X 672 KR

## (54) IMPROVEMENTS IN OR RELATING TO EXTRACTING ALKALOIDS FROM ERGOT OF RYE

- (71) We, LEK TOVARNA FARMACEVTSKIH  
 IN KEMICNIH IZDELKOV, a Yugoslavian Body  
 Corporate, of Celovska c. 135, Ljubljana,  
 Yugoslavia, do hereby declare the invention,  
 for which we pray that a patent may be  
 granted to us, and the method by which it is  
 to be performed, to be particularly described  
 in and by the following statement:—  
 The invention relates to a process for the  
 isolation of alkaloids from the ergot of rye.  
 When isolating the ergot-alkaloids, their  
 decomposability and conversion into inactive  
 isomers has to be taken into account. For this  
 reason the process should be accomplished  
 rapidly, in order that the large quantity of  
 ballast substances, mainly fats, do not effect  
 the process.  
 Prior art procedures utilize a preliminary  
 purification, e.g. extraction. This prolongs the  
 reaction times, but causes considerable losses  
 of alkaloids and undesirable isomerisation.  
 More recent processes omit the preliminary  
 extraction. However, this has numerous other  
 drawbacks. Whether the extracts are con-  
 centrated or various additives are used to  
 prevent the formation of emulsions, the  
 alkaloids are exposed to the action of heat  
 and various reagents. The removal of the  
 ballast substances requires a repeated transfer  
 of the alkaloids from one solvent into another  
 which prolongs the isolation procedure,  
 lowers the yield and reduces the quality of the  
 product.  
 The process according to the invention as  
 hereinafter exemplified avoids the above-  
 mentioned drawbacks to a high degree. The  
 preliminary extraction is not necessary and  
 separation of the alkaloids from the ballast  
 substances proceeds easily and rapidly.  
 According to the present invention there is  
 provided a process for the isolation of ergot-  
 alkaloids which process comprises extracting  
 ground ergot of rye with an organic water-  
 immiscible solvent, contacting the resultant  
 extract with an adsorbent material in order to  
 reversibly adsorb the alkaloids, desorbing the  
 alkaloids by means of a solvent which is more  
 polar than the solvent used for the extraction,  
 concentrating the resultant eluate *in vacuo* and  
 thereafter precipitating the alkaloid by the  
 addition of petroleum ether.  
 The drug is extracted with an organic,  
 water-immiscible solvent, such as: chloro-  
 form, benzene, trichloroethylene, toluene,  
 methylene chloride, or dichloroethane. The  
 extract is filtered through a column of a  
 suitable adsorbent, preferably alumina,  
 whereby the alkaloids and small quantities of  
 the ballast substances are adsorbed, whereas  
 the greater part of the ballast substances are  
 transferred into the filtrate. The adsorbed  
 alkaloids are then eluted with a much smaller  
 quantity of a more polar solvent or a mixture  
 of the above-mentioned solvents with meth-  
 anol or ethanol. Subsequently the eluate is  
 concentrated to  $\frac{1}{20}$  of its volume and  
 separated from the major part of the ballast  
 substances remaining on the adsorbent. The  
 alkaloids are isolated from the eluate by  
 careful evaporation of the solvent *in vacuo* and  
 precipitation in an excess of petroleum ether.  
 The process of adsorption and desorption of  
 the alkaloids can be followed in UV-light.  
 The same effect is attained by suspending the  
 adsorbent in the extract or eluate and separa-  
 ting it by filtration.  
 The process according to the invention is  
 illustrated in detail by the following example:
- EXAMPLE
- 10 kg. of ground ergot of rye is extracted  
 in the usual manner with trichloroethylene.  
 50 litres of the extract is passed through two  
 75 g. columns of active alumina over a period  
 of 2 hours. The active alumina is contained in  
 two glass columns with a diameter of 10 cm.  
 and a length of 50 cm. The alkaloids are eluted  
 with 2 litres of ethyl acetate and the eluate is  
 concentrated to a volume of about 150 cc.  
 The alkaloid-bases are precipitated by pouring  
 the concentrate into a tenfold quantity of  
 petroleum ether filtered off and dried in a  
 vacuum drier.  
 The yield amounts to 90% of the alkaloids

BEST AVAILABLE COPY

2  
3  
4  
5 contained in the drug, in the form of a whitish amorphous powder containing 85 to 90%, with respect to the ergotamin-base. The percentage of the dextrorotatory isomers is practically the same as in the drug.

WHAT WE CLAIM IS:—

10 1. A process for the isolation of ergot-alkaloids which process comprises extracting ground ergot of rye with an organic water-immiscible solvent, contacting the resultant extract with an adsorbent material in order to reversibly adsorb the alkaloids, desorbing the alkaloids by means of a solvent which is more polar than the solvent used for the extraction, 15 concentrating the resultant eluate *in vacuo* and thereafter precipitating the alkaloid by the addition of petroleum ether.

20 2. A process as claimed in claim 1 wherein the organic-water immiscible solvent is chloroform, benzene, trichlorethylene, toluene, methylenechloride or dichloroethane.

3. A process as claimed in claim 1 or

claim 2 wherein the adsorbent material is alumina.

4. A process as claimed in any of the preceding claims wherein the solvent used to desorb the alkaloid is ethyl acetate. 25

5. A process as claimed in any one of claims 1 to 3 wherein the solvent used to desorb the alkaloid is a mixture of the organic water-immiscible solvent and methanol or ethanol. 30

6. A process for the isolation of ergot-alkaloids as claimed in claim 1 substantially as described herein in the foregoing example. 35

7. Ergot-alkaloids whenever isolated by the process as claimed in any one of the foregoing claims.

LEK TOVARNA FARMACEVTSKIH  
IN KEMICNIH IZDELKOV.  
Per: BOULT, WADE & TENNANT,  
112, Hatton Garden,  
London, EC1N 8NA,  
Chartered Patent Agents.

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon), Ltd.—1972.  
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY,  
from which copies may be obtained.

BEST AVAILABLE COPY